AVTX
Avalo Therapeutics Inc
13.40$
-1.1%
vs. previous close
Closing price · As of: Oct 8, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | – | – | 100.0% | 100.0% | – | – | – | 100.0% | – | – | 100.0% | |
| 101.7% | -38.7% | – | – | -286.7% | 45.3% | – | – | – | 27.1% | – | – | – | |
| -1.7% | 138.7% | – | – | 386.7% | 54.7% | – | – | – | 100.0% | – | – | – | |
| 529.2% | 327.0% | – | – | 3,830.5% | 4,262.0% | – | – | – | 22,486.4% | – | – | 109,072.9% | |
| 1,055.1% | 467.4% | – | – | 1,664.3% | 2,314.6% | – | – | – | 10,428.8% | – | – | 44,945.8% | |
| 1,587.3% | 795.6% | – | – | 5,551.8% | 6,987.5% | – | – | – | 33,561.0% | – | – | 137,983.1% | |
| -1,589.0% | -656.9% | – | – | -5,165.1% | -6,932.8% | – | – | – | -33,461.0% | – | – | -154,844.1% | |
| 658.1% | 14.2% | – | – | 387.1% | – | – | – | – | – | – | – | – | |
| -2,211.9% | -1,432.0% | – | – | 9,246.2% | -18,346.4% | – | – | – | -23,033.9% | – | – | -169,766.1% | |
| 3.4% | -1.6% | – | – | -5.6% | 59.4% | – | – | – | 220.3% | – | – | 289.8% | |
| -2,215.3% | -1,430.5% | – | – | 9,251.8% | -18,405.7% | – | – | – | -23,254.2% | – | – | -170,055.9% | |
| -1,536.4% | -1,438.7% | – | – | 9,259.8% | -18,310.9% | – | – | – | -23,006.8% | – | – | -169,581.4% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 8, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.